In Brief: Apothecus Pharmaceutical
This article was originally published in The Tan Sheet
Executive Summary
Apothecus Pharmaceutical: Informs FDA in a July 26 letter that the company will forward the protocol for an upcoming study using its VCF Vaginal Contraceptive Film to agency. The open-label, prospective, parallel group, randomized, multicenter clinical trial will compare VCF to a foaming tablet contraceptive and will be conducted by Family Health International. FDA's Feb. 3 tentative final monograph requires approved NDAs in order to continue marketing OTC vaginal contraceptive products ("The Tan Sheet" Feb. 6, pp. 2-4). Apothecus, which sells VCF to public agencies for distribution to inner-city teens, has opposed the requirement because of the high costs associated with conducting clinical trials ("The Tan Sheet" June 19, p. 9)...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning